Integrase Inhibitors in Development
- Way-Long-Acting Integrase Inhibitor for PrEP?: One Study Whose Impact Will Last Well Beyond CROI 2013 (March 14, 2013)
In The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), from TheBodyPRO.com
- Long-Acting PrEP Injection Prevents Anal Simian HIV Transmission (March 13, 2013)
From AIDSmeds.com
- Dolutegravir Appears Superior to Raltegravir Among HIV Salvage Patients (March 11, 2013)
From AIDSmeds.com
- New Integrase Inhibitor Dolutegravir Helps Treatment-Experienced People on Failing Therapy (March 10, 2013)
From aidsmap.com
- Dolutegravir Helps Highly-Resistant Treatment-Experienced People on Failing ART (March 8, 2013)
From HIVandHepatitis.com
- Dolutegravir Superior to Raltegravir in ART-Experienced Integrase Inhibitor Naive at 24 Weeks (March 6, 2013)
From National AIDS Treatment Advocacy Project
- Long-Acting Integrase Inhibitor Shields Macaques From Anal Simian HIV (March 4, 2013)
From National AIDS Treatment Advocacy Project
- Monthly Injectable Drug Offers 100% Protection Against HIV in Monkeys -- Could Be Dosed Every Three Months (March 4, 2013)
From aidsmap.com
New HIV Drug Dolutegravir Could Soon Be Approved by FDA (February 28, 2013)
From TheBodyPRO.com
- Dolutegravir: Integrase Resistance and the Impact of the Background Regimen (November/December 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
VIEW ALL ARTICLES
Email
Glossary
